Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

XTX301

Fusion protein · Immune activation · developed by Xilio Development

Phase 1/2 Most advanced trial
XLO Developer
1 Registered trials

What is XTX301?

XTX301 is an engineered IL-12 cytokine conjugated to a masking domain and a half-life extension domain, joined by a tumor protease-cleavable linker. The masking domain keeps IL-12 inactive in circulation; MMP cleavage in the tumor microenvironment releases active IL-12 to activate CD8+ and CD4+ T-cells and natural killer cells. It is studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Fusion protein
Mechanism
Immune activation
Pathways
IFN-gamma secretion, CD8+ T-cell activation, CD4+ T-cell activation, natural killer cell activation
Therapy area
Oncology
Developer
Xilio Development, Inc. (XLO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05684965 Phase 1/2 Advanced Solid Tumor Recruiting XLO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor

More from Xilio Development

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XLO page.

Follow XLO, the company behind XTX301

See XLO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XLO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.